Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
NCT03197389
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
54
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Triple Negative Breast Cancer
Hormone Receptor Negative Neoplasm
Interventions
DRUG:
Pembrolizumab
Sponsor
Universitaire Ziekenhuizen KU Leuven